SOAT1 and rheumatoid arthritis: Perhaps extrapolating from the efficacy and safety of tofacitinib in the treatment of patients with RA [5] and the considerable basic data linking the JAK-STAT pathway with the regulation of immune function [60], Sandborn et al. published the first clinical trial of tofacitinib in patients with moderate-to-severe UC in 2012 [61], showing promising results.